P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantationECCO '18 Vienna
2018
P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studiesECCO '18 Vienna
2018
P498: Crohn’s disease patient’s isolated classical monocytes are characterised by reduced secretion of Wnt-ligands affecting Paneth cell antimicrobial host defenseECCO '18 Vienna
2018
P499: A comparison of health-related quality of life in nurse-led vs. conventional inflammatory bowel disease follow-upECCO '18 Vienna
2018
P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?ECCO '18 Vienna
2018
P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reportsECCO '18 Vienna
2018
P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control studyECCO '18 Vienna
2018
P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?ECCO '18 Vienna
2018
P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's diseaseECCO '18 Vienna
2018
P505: Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospitalECCO '18 Vienna
2018
P506: Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims databaseECCO '18 Vienna
2018
P507: What is the impact of infliximab metaoptimisation on surgical rates and need-to-change-therapy in real-world practice for severe inflammatory bowel disease?ECCO '18 Vienna
2018
P508: Response of hepatitis B vaccination in patients with inflammatory bowel disease; prospective observational study in KoreaECCO '18 Vienna
2018
P510: Hypergammaglobulinemia, hypoalbuminemia, and elevated CRP levels are predictors of a secondary loss of response to anti-TNFα therapy in IBDECCO '18 Vienna
2018
P512: Herpes zoster infection in patients with ulcerative colitis receiving tofacitinibECCO '18 Vienna
2018
P513: Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: Ten-year follow-up data from the Swiss IBD cohort studyECCO '18 Vienna
2018